

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

BKSH & ASSOCIATES

2. Address:

1801 K ST NW STE 901-L, WASHINGTON, DC 20006

3. Principal place of business (if different from line 2):

4. Contact Name: MARY KAY MORIN

Telephone: 202-530-0500

E-mail (optional): mary_kay_morin@was.bm.com

Senate ID #: 6291-354

House ID #: 33118014

7. Client Name: ☐ Self

GENENTECH

TYPE OF REPORT

8. Year 2002 Midyear (January 1 - June 30): ☐ **OR** Year End (July 1 - December 31): ☒

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☒ => Termination Date: Dec 31, 2002 11. No Lobbying Activity: ☐

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 20,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S. 812/H.R. 1862, Greater Access to Affordable Pharmaceuticals Act of 2001; H.R. 3448/S. 1765, Public Health Security and Bioterrorism Preparedness and Response Act of 2001 (P.L. 107-188); and H.R. 698, Prescription Reimportation, Improvement, Correction and Enhancement Act.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BODE, HOLLY

Covered Official Position (if applicable): N/A

Name: BROWN, PAUL

Covered Official Position (if applicable): N/A

Name: KLEPNER, JERRY

Covered Official Position (if applicable): N/A

Name: MERIN, CHARLES L.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MED (one per page)

16. Specific lobbying issues:

S. 30, Financial Information Privacy Protection Act of 2001; H.R. 2505/S. 2172, cloning of embryos.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BODE, HOLLY

Covered Official Position (if applicable): N/A

Name: BROWN, PAUL

Covered Official Position (if applicable): N/A

Name: KLEPNER, JERRY

Covered Official Position (if applicable): N/A

Name: MERIN, CHARLES L.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R. 4954, The Medicare Modernization and Prescription Drug Act of 2002; S. 2675, Medicare Outpatient Prescription Drug Act of 2002; and S. 2729, 21st Century Medicare Act.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BODE, HOLLY

Covered Official Position (if applicable): N/A

Name: BROWN, PAUL

Covered Official Position (if applicable): N/A

Name: KLEPNER, JERRY

Covered Official Position (if applicable): N/A

Name: MERIN, CHARLES L.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

Medical innovation research tax credit.

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BODE, HOLLY

Covered Official Position (if applicable): N/A

Name: BROWN, PAUL

Covered Official Position (if applicable): N/A

Name: KLEPNER, JERRY

Covered Official Position (if applicable): N/A

Name: MERIN, CHARLES L.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Feb 10, 2003

Printed Name and Title: MARY KAY MORIN - FEDERAL COMPLIANCE ADMINISTRATOR